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Abstract
Background:  Past studies suggested that tumor necrosis factor (TNF) assisted anti-tumor
treatment and intensified the sensitivity of chemotherapy. However its clinical application has been
curbed because of its low purity, high dosage, and strong toxicity. This research, through
perspective random clinical control experiment, observed the therapeutic effect of the treatment
of late malignant tumor through the injection of recombinant mutant human tumor necrosis factor
(rmhTNF) combined with general chemotherapy and its adverse reactions.
Methods: 105 patients with advanced malignant tumor were randomly divided into trial group, 69
patients, and control group, 36 patients. Injection of rmhTNF 4 × 106u/m2 was given to the trial
group, from the 1st to 7th days, the 11th to 17th days combined with chemotherapy course. The
chemotherapy plan was as follows: CAP for patients with the NSCLC; FAM for patients with gastric
cancer; FC for patients with colorectal cancer. One treatment cycle lasted for 21 days and two
cycles were scheduled. The control group was given only the same chemotherapy as the trial group.
Results: In the trial group there was 1 CR case and 12 PR cases, and the response rate is 13/69
(18.84%); in the control group 1 PR case, the response rate 1/36 (2.78%). The response rate of the
trial group was significantly higher than that of the control group (P = 0.022). The response rate
for NSCLC in the trial group was 8/17 (47.06%), and 1/6 (16.67%) in the control group. The
response rates for gastric cancer and colorectal cancer in the trial groups also were higher than
those of the control groups. After the treatment the KPS is 89.00 ± 9.92 in the trial group, and
84.17 ± 8.84 in the control group, with a significant difference between the two groups (P = 0.028).
The adverse reactions of rmhTNF injection included: pain in the injection area, chill, hardening and
swelling and redness in the injection area, fever, ostealgia and myosalgia, and cold-like symptoms.
All these adverse reactions were mild and bearable.
Conclusions: The administration of rmhTNF injection in combination with general chemotherapy
is an effective and secure means in treating advanced malignant tumor.
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Tumor necrosis factor (TNF) is a polypeptide produced by
monocytic macrophages and T-lymphocytes stimulated
by endotoxin[1]. It has been well shown in vivo or in vitro
that TNF assists anti-tumor treatment and intensified the
sensitivity of chemotherapy to many different kinds of
tumor cells [2-5]. However its clinical application has
been curbed because of its low purity, high dosage, and
strong toxicity. Via the cooperation between the Forth
Military Medical University and Shanghai Celstar Bio-
pharmaceutical Holding Co. Ltd, an injection of recom-
binant mutant human tumor necrosis factor (rmhTNF)
which is a genetic engineering TNF of a high activity and
low toxicity, has been produced by rebuilding natural TNF
with protein engineering technics. Phase I clinical trial
(tolerance test) showed that the patients had good toler-
ance. and the toxicity of rmhTNF was slight As a partici-
pant of the Phase II and Phase III clinical study of
rmhTNF, we observed the therapeutic effect of the treat-
ment of late malignant tumor through the injection of
recombinant mutant human tumor necrosis factor com-
bined with general chemotherapy and its toxicity in a
multi-center, random clinical control Phase II and Phase
III clinical study of rmhTNF during October 2000 ~ May
2002. The results are reported as below.
1. Materials and Methods
1.1 Patients
105 patients from our department with advanced malig-
nant tumors diagnosed via pathologic or cytological
examinations were randomly collected, of which 23 were
non-small cell lung cancer, 50 gastric cancers and 32 were
colorectal cancers. Moreover, 79 of them were males and
26 of them were females. The range of their ages was
25~70, with the median age 52 years old. All of them were
during their later phases of either recrudescent or meta-
static cancers, had no sugary indexes and were taking con-
servative medicine treatment. KPS scoring for them before
treatment were ≥ 60, neutrophil ≥ 2.0 × 109/L, PLT ≥ 100
× 109/L and Hb ≥ 90 g/L. They had almost normal func-
tions of the heart, liver and kidney and at least had one
evaluable tumor focus. They had not taken any other anti-
tumor treatment one month before the experiment and
they had a prospective survival time > 3 months. All of the
patients were well informed and written consents were
signed. Then they were randomly divided into two
groups, i.e. the trial group of 69 patients and the control
group of 36 patients, the conditions of the two groups
were comparable (P >0.05, see Table 1). In the individual
group of three tumors, the stage of the disease is of no
significant difference (P >0.05, see Table 1).
1.2 Source of drugs
Injection of rmhTNF which was in powder form of 500 ×
105u/tube (number 00061) was made and provided by
the Forth Military Medical University and was stored at
4°C in refrigerator.
Table 1: The General Data of the Trial and Control Group
Item Trial group (n = 69) Control group (n = 36) P
Sex 0.362
Male 50 29
Female 19 7
Median age (year) 52 51 0.437
Type of tumors 0.638*
NSCLC 17 6
Gastric cancer 32 18
Colorectal cancer 20 12
KPS ( ) 85.31 ± 6.07 86.69 ± 7.81 0.334
Clinical stage 0.630
III 11 8
IV 58 28
NSCLC III 5 3 0.621*
IV 12 3
Gastric cancer III 4 3 0.684
IV 28 15
Colorectal cancer III 2 2 0.620*
IV 18 10
*The p value is calculated by Fisher exact chi-square because n < 30 or some cells have expected count less than 1.
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1.3 Treatment protocol
For the trial group, injection of rmhTNF 4 × 106u/m2 was
given from the 1st to 7th days, the 11th to 17th days com-
bined with chemotherapy course. The chemotherapy plan
was as follows: CAP (CTX 750 mg/m2, d1, ADM 40 mg m2,
d1, DDP 30 mg m2, d1-d3) for patients with the non-small
cell lung cancer; FAM (5-FU500 mg/ m2, d1-d5, ADM 40
mg/ m2, d1, MMC 6 mg/ m2, d1) for patients with gastric
cancer; FC (5-FU 500 mg/ m2, d1-d5, CF 100 mg/ m2, d1-
d5) for patients with colorectal cancer. One treatment
cycle lasted for 21 days and two cycles were scheduled. For
the control group, only the same chemotherapy as the
trial group was given. Signs, symptoms and adverse reac-
tions were carefully observed during the treatment.
Weekly examinations of blood routine were performed
before and after treatment, while liver and kidney func-
tions, urine routine, EEG, liver ultrasonic and chest X-ray
examinations were performed before and after every treat-
ment cycle. CT examinations of the evaluable tumor
focuses were performed one time before treatment, when
treatments were finished and after 4 weeks of the finish.
1.4 Evaluation of response and toxicity
1.4.1 Evaluation of response
Complete response (CR) is that, the disappearance of all
lesions and no appearance of new disease for at least 4
weeks. Partial response (PR) is defined as a reduction by
at least 50% in the sum of the products of the two longest
diameters of all lesions maintained for at least 4 weeks
with no appearance of new disease. Minimal response
(MR) is different from PR with a reduction by at least
25%, but not more than 50%. Stable disease (SD) is a less
than 25% reduction or less than 25% increase in the sum
of the products of the two perpendicular diameters of all
measured lesion with no appearance of new disease. Pro-
gression disease (PD) is that, an increase greater than 25%
over the size present at entry into the study or, for patients
who respond, the size at time of maximum regression, or
the appearance of new areas of malignant disease. CR+PR
were rated as response rate.
1.4.2 Toxicity
The toxicity was followed the WHO acute and sub-acute
toxic rating
2. Results
2.1 Response to treatment
After two treatment cycles, the trial group had 1 CR case,
12 PR cases, 11 SD cases and 18 PD cases, and the
response rate was 13/69(18.84%). The control group, on
the other hand, had 1 PR case, 4 MR cases, 19 SD cases and
12 PD cases, and had a response rate 1/36 (2.78%). The
response rate of the trial group was significantly higher
than that of the control group (P = 0.022, see Table 2).
The response rate for NSCLC of the trial group was 8/17
(47.06%), higher than that of the control group 1/6
(16.67%) but without statistic significance (P = 0.208).
The response rates for gastric cancer was 12.50% (4/32),
while for the controls were 0.00% (0/18) without statistic
significance (P = 0.283). The response rates for colorectal
cancer was 5.00% (1/20), while no response case in the
controls group (0/12), but there was still no statistic sig-
nificance (P = 1.000, see Table 3).
2.2 Life quality
Before the treatment there was no significant difference of
the general status (KPS) between the two groups (P  >
0.05). After the treatment the KPS was 89.00 ± 9.92 in the
trial group, and 84.17 ± 8.84 in the control group, with a
statistic significant difference (p = 0.028, see Table 4).
2.3 Toxicity
Fever, cold-like symptoms, ostealgia and myosalgia, chill,
pain in the injection area, hardening and swelling and
redness in the injection area were much more happened
in the trail group compared with the control group (P <
0.01 = , while there were no significant differences
between the two groups on the frequencies of anemia,
leukopenia, thrombocytopia and nausea / vomiting (P >
0.05). No abnormalities correlated with drugs were found
in liver or kidney functions, urine routine, EEG and blood
pressure (see Table 5).
3. Case report
A 54-year-old man hospitalized at August 27, 2001 with
complains of "left chest pain accompanied by cough and
hard breath for half a month". Physical examination after
hospitalization showed: enlarged lymph node of 3 × 3 cm
above the right clavicle, hard and immobile. Chest CT on
September 27, 2001 (see Figure 1) showed: conglomera-
tion of a size of 5.5 × 4.2 cm at the left lower hilus pulmo-
nis, large amount of accumulation of fluid in the left
thoracic cavity, enlarged lymph nodes in the mediasti-
num. Biopsy of the lymph node above the right clavicle
showed: transferred adenocarcinoma. Cancer cells were
found in the fluid in the thoracic cavity after centrifuga-
tion. The diagnosis was "Adenocarcinoma on the left
lower lung, stage T4N3M0IIIb". Chemotherapy of protocol
CAP + rmhT NF injection (i.m.) was given from October
4 to November 14, 2001. Two weeks later, a clear relief of
hard breath and cough was found. After two periods of
therapy (November 16, 2001), physical examination
showed shrinkage of lymph node of 0.5 × 0.5 cm above
the right clavicle, and Chest CT (see Figure 2) showed:
clear shrinkage of conglomeration of 3.0 × 2.5 cm at the
left lower hilus pulmonis, small amount of accumulation
of fluid in the left thoracic cavity. A callback of CT one
month later showed: conglomeration was of the size of
4.0 × 2.8 cm. The curative effect was confirmed as "PR".Journal of Translational Medicine 2004, 2:33 http://www.translational-medicine.com/content/2/1/33
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Table 2: The Response Rate in the Trial and Control Group after Two Treatment Cycles
Group n CR PR MR SD PD Response rate P
Trial 69 1 12 11 27 18 13/69 (18.84%) 0.022
Control 36 0 1 4 19 12 1/36 (2.78%)
Table 3: The Response Rate in the Trial and Control Group for Different Type of Tumors
Group n CR PR MR SD PD Response rate p*
N S C L C T r i a l 1 7 17342 4 7 . 0 6 %  ( 8 / 1 7 ) 0 . 2 0 8
C o n t r o l 601131 1 6 . 6 7 %  ( 1 / 6 )
Gastric cancer Trial 32 0 4 6 13 9 12.50% (4/32) 0.283
C o n t r o l 1 8 00297 0 . 0 0  ( 0 / 1 8 )
Colorectal cancer Trial 20 0 1 2 10 7 5.00% (1/20) 1.000
C o n t r o l 1 2 00174 0 . 0 0  ( 0 / 1 2 )
*The p value is calculated by Fisher exact chi-square because n < 30 or some cells have expected count less than 1.
Table 4: Before and after Treatment, KPS Value in the Trial and Control Group
Group Trial (n = 69) Control (n = 36) P
Before treatment ( ) 85.31 ± 6.07 86.69 ± 7.81 0.334
After treatment ( ) 89.00 ± 9.92 84.17 ± 8.84 0.028
Table 5: Toxicity in the Trial and Control Group
Toxicity Trial (n = 69) Control (n = 36) P*
0 I II III IV 0 I II III IV
A n e m i a 3 7 1 6 871 2 1 9411 0 . 6 6 5
L e u k o p e n i a 2 8 2 3 990 1 7 1 3 420 0 . 5 7 0
T h r o m b o c y t o p i a 5 9 5221 3 1 3110 0 . 5 5 7
Nausea / Vomiting 32 16 19 2 0 18 4 11 2 1 0.476
F e v e r 5 2 1 2 500 3 6 0000 0 . 0 0 0
E r u p t i o n 6 7 2000 3 6 0000 0 . 2 7 4
Cold-like symptoms 47 19 3 0 0 36 0 0 0 0 0.000
Ostealgia / Myosalgia 46 21 2 0 0 36 0 0 0 0 0.000
Chill 38 31 0 0 0 36 0 0 0 0 0.000
Pain in injection area 13 41 15 0 0 36 0 0 0 0 0.000
Hardening, swelling and redness in injection area 42 17 10 0 0 36 0 0 0 0 0.000
*The p value is calculated by Fisher exact chi-square because n<30 or some cells have expected count less than 1.
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4. Discussion
Tumor necrosis factor (TNF) is a polypeptide produced by
monocytic macrophages and T-lymphocytes stimulated
by endotoxin. It can act as modulator to immunity and
induces anti-tumor effects in hosts. It also has direct cyto-
toxic effects and inhibitory effects on cellular growth. It
can kill the tumor cell without notable toxic effect on the
normal cells [1]. Studies have shown that the anti-tumor
Chest CT before treatment (27-Sep-2001) show that conglomeration of a size of 5.5 × 4.2 cm at the left lower hilus pulmonis,  large amount of accumulation of fluid in the left thoracic cavity, enlarged lymph nodes in the mediastinum Figure 1
Chest CT before treatment (27-Sep-2001) show that conglomeration of a size of 5.5 × 4.2 cm at the left lower hilus pulmonis, 
large amount of accumulation of fluid in the left thoracic cavity, enlarged lymph nodes in the mediastinum.Journal of Translational Medicine 2004, 2:33 http://www.translational-medicine.com/content/2/1/33
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mechanism of the tumor necrosis factor includes 1) kill-
ing the tumor cell directly [3]; 2 inducing the apoptosis of
tumor cells [3]; 3) reversing more drug resistance of tumor
cell and improving the sensitiveness of chemotherapy [3];
4) destroying the blood supply of tumor tissue [4]; 5)
increasing the killing effects of immune-effect cells on the
tumor cells [3]. However, its clinical application has been
curbed because of its low purity, high dosage, and strong
toxicity. Studies have also shown that, a higher anti-tumor
effect and lower toxicity were got by modified some struc-
Chest CT after treatment (16-Nov-2001) show that clear shrinkage of conglomeration of 3.0 × 2.5 cm at the left lower hilus  pulmonis, small amount of accumulation of fluid in the left thoracic cavity Figure 2
Chest CT after treatment (16-Nov-2001) show that clear shrinkage of conglomeration of 3.0 × 2.5 cm at the left lower hilus 
pulmonis, small amount of accumulation of fluid in the left thoracic cavity.Journal of Translational Medicine 2004, 2:33 http://www.translational-medicine.com/content/2/1/33
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ture of TNF. Nakamura [6] prepared a novel recombinant
tumor necrosis factor-α (TNF) mutant (mutant 471), in
which 7 N-terminal amino-acids were deleted and
Pro8Ser9Asp10 was replaced by Arg-Lys-Arg, and compared
its biological activity with that of wild-type recombinant
TNF. Mutant 471 had a 7-fold higher anti-tumor activity
against murine L-M cells in vitro, and a higher binding
activity to TNF receptors on L-M cells, than wild-type TNF.
Kamijo[7] reported that TNF(C-Phe), in which the C-ter-
minal leucine of TNF molecule was replaced by phenyla-
lanine, was 20-times as potent in induction of
differentiation of human myelogenous leukemia cells (U-
937 cells) as the parent TNF(N-Met). The rmhTNF has
been obtained successfully from hTNF-α by gene engi-
neering technology which was mutated by deleting 7
amino acids at the N-terminus, replacing Pro8Ser9Asp10 by
Arg-Lys-Arg, and substituting Leu157 with Phe [8]. Phrase
I clinical trial indicated that, all of 32 patients who were
randomly grouped into six groups were treated with dif-
ferent dose: 2.5 × 105u/m2, 5 × 105u/m2, 1 × 106u/m2, 2 ×
106u/m2, 3 × 106u/m2, 4 × 106u/m2, were well tolerable.
The present study has shown that shortly after the com-
bined chemotherapy with rmhTNF, 24/69 (34.78%) of
the focuses were more or less absorbed or subsidized, of
which there were 1 CR case and 12 PR cases, with the
response rate was 13/69 (18.84%), while in the control
group only 5/36 (13.89%) cases had reduced focuses with
only 1 PR case and the response rate 1/36 (2.78%). The
response rate of the trial group was significantly higher
than that of the control group (P = 0.022). Analysis of the
therapeutic effects in different kind of diseases showed
that the response rate for NSCLC of the trial group was 8/
17 (47.06%), higher than that of the control group 1/6
(16.67%), which also means that TNFα has suppressive
effects on lung adenocarcinoma[9]. The reason why there
was no statistic significance (P > 0.05) between the two
groups may be due to too small samples in this investiga-
tion. The response rates for gastric cancer and the colorec-
tal cancer were both quite low, i.e. 4/32 (12.50%) and 1/
20 (5.00%), respectively, while for the controls were 0/18
and 0/12, respectively (0.00%) and without statistic sig-
nificance (P > 0.05). Such a result may be mainly due to
the fact that most of the patients had taken combined
chemotherapy before and that samples in both groups
were quite small. It was thought [2] that the anti-tumor
activity of TNF may co-activate some chemotherapy drugs.
Results of the present study showed that the combined
therapy of TNF and chemotherapy may be still effective on
previously chemotherapy drug resistant tumors, which
also means that TNF has co-activating effects on chemo-
therapy drugs. Moreover, after two treatment cycles, scor-
ing for the general status (KPS) was 89.00 ± 9.92 in the
trial group and 84.17 ± 8.84 in the control group, with a
statistic significant difference (P = 0.028). It shows that
the combined rmhTNF chemotherapy may benefit the
quality of the patients' life.
It has already been reported[2-5,10,11] that the toxicity of
TNF in phase I or II clinical trials are mainly chill, fever,
local redness, swelling and pain, hypotension, nausea,
vomiting, myalgia, fatigue and diarrhea, while pulmonary
hemorrhage and severe hepatic dysfunction also have
been observed[12]. But there are no reports on the toxicity
of rmhTNF. The present study showed that some of the
patients had pain in the injection area, chill and harden-
ing, swelling and redness in the injection area of which
the incidences were 81.2%(56/69), 44.9%(31/69) and
39.1% (27/69), respectively, but of a low degree and the
patients had good tolerance. The symptoms of fever,
ostealgia and myosalgia and cold-like symptoms were
more in the trail group than that in the control group, all
of which were of grade I or II. They mainly happened
when the drugs were given at the 3rd or 5th times, and can
be relieved after taking 25 mg metacen, and can disappear
automatically after the finish of the therapy. There were
no significant differences between the two groups on the
number of cases which showed marrow suppression or
nausea / vomiting, and on the degree of those symptoms.
There were no cases which showed rmhTNF-correlated
abnormal liver or kidney functions, urine routine, EEG
and blood pressure.
In summary, combined therapy of rmhTNF and chemo-
therapy has co-activating and sensitivity improving effects
on the treatment of advanced malignant tumors, and may
increase the recent responsive effectiveness with an
improvement of the general status and quality of patients'
lives. The main adverse reactions of the local injection of
rmhTNF are pain in the local injection area, chill, harden-
ing and swelling and redness in the injection area, fever,
ostealgia and myosalgia and cold-like symptoms, all of
which were of light to moderate degree and are tolerable.
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